Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Medicenna Therapeutics Corp. (T.MDN) had Stock-Based Compensation of 0.28M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-3.56M |
|
-- |
|
-- |
|
-- |
|
-3.98M |
|
-- |
|
-3.56M |
|
-3.56M |
|
-3.56M |
|
-3.56M |
|
-3.56M |
|
-3.56M |
|
-3.98M |
|
-3.97M |
|
82.52M |
|
82.52M |
|
-0.04 |
|
-0.04 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
16.46M |
|
-- |
|
-- |
|
-- |
|
5.88M |
|
10.58M |
|
10.55M |
|
10.58M |
|
83.38M |
|
| Cash Flow Statement Financials | |
-2.56M |
|
-- |
|
0.03M |
|
17.95M |
|
14.79M |
|
-3.16M |
|
|
Stock-Based Compensation |
0.28M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.94 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-2.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.66% |
|
-33.77% |
|
-21.64% |
|
-33.42% |
|
0.18 |
|
-0.03 |
|
-0.03 |
|